Werewolf Therapeutics (HOWL)
(Delayed Data from NSDQ)
$2.94 USD
+0.20 (7.30%)
Updated Jul 23, 2024 04:00 PM ET
After-Market: $2.94 0.00 (0.00%) 7:58 PM ET
3-Hold of 5 3
F Value F Growth C Momentum F VGM
Fundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
HOWL 2.94 +0.20(7.30%)
Will HOWL be a Portfolio Killer in July?
Zacks Investment Research is releasing its prediction for HOWL based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for HOWL
All You Need to Know About Werewolf Therapeutics (HOWL) Rating Upgrade to Buy
How Much Upside is Left in Werewolf Therapeutics, Inc. (HOWL)? Wall Street Analysts Think 92.37%
HOWL: What are Zacks experts saying now?
Zacks Private Portfolio Services
Werewolf Therapeutics, Inc. (HOWL) Reports Q4 Loss, Lags Revenue Estimates
TScan Therapeutics, Inc. (TCRX) Reports Q4 Loss, Tops Revenue Estimates
Strength Seen in Exelixis (EXEL): Can Its 5.6% Jump Turn into More Strength?
Other News for HOWL
Optimistic Buy Rating for Werewolf Therapeutics Backed by Promising Early WTX-330 Trial Results
Where Werewolf Therapeutics Stands With Analysts
Buy Rating Affirmed for Werewolf Therapeutics Amid Promising WTX-330 Clinical Data and PREDATOR Platform Potential
Buy Rating Affirmed: Promising WTX-330 Trial Results and Strategic Partnerships Bolster Werewolf Therapeutics’ Outlook
Werewolf Therapeutics Highlights Initial Safety and Efficacy Data from its Ongoing Phase 1 Clinical Trial Evaluating WTX-330 in Patients with Advanced or Metastatic Solid Tumors or Non-Hodgkin Lymphoma